William Blair & Company
CMPX icon

William Blair & Company’s Compass Therapeutics CMPX Stock Holding History

William Blair & Company’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.7K Sell
12,186
-18,574
-60% -$54.8K ﹤0.01% 1833
2026
Q1 		$163K Buy
+30,760
New +$178K ﹤0.01% 1517

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

William Blair & Company's CMPX Position: Q2 2026 in Review

William Blair & Company reduced its Compass Therapeutics (CMPX) stake by 60% in Q2 2026, selling an estimated $54.8K and leaving 12,186 shares worth $26.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

William Blair & Company first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $163K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • William Blair & Company held 12,186 shares of Compass Therapeutics worth $26.7K as of Q2 2026.
  • William Blair & Company sold 18,574 Compass Therapeutics shares in Q2 2026, an estimated $54.8K.
  • Compass Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1833 holding.
  • William Blair & Company first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • William Blair & Company's Compass Therapeutics position peaked at $163K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.